Women's Health · LP-102
Ferrous sulfate + folic acid Tablets
Generic medicine development record. Review the proposed presentation and the professional reference information below.
Development record
- Portfolio reference
- LP-102Women's Health
- Generic identity
- Ferrous sulfate + folic acidTablet
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Ingredient reference
Record identity and reference background.
- Portfolio reference
- LP-102
- Generic ingredient
- Ferrous sulfate + folic acid
- Dosage form
- Tablet
- Proposed strength
- Ferrous sulfate equivalent to 60 mg elemental iron + 400 mcg folic acid
- Proposed pack
- Blister 10 x 10 tablets; bottle 1000 for programs
- Portfolio category
- Women's Health
About Ferrous sulfate + folic acid
Iron and folic acid provide nutrients needed for normal red-blood-cell production. An iron component supports haemoglobin formation, while folate contributes to DNA synthesis and cell division. A combined tablet can be relevant to defined supplementation or deficiency-management programmes, but anaemia has multiple causes. Ingredient inclusion does not establish that a person is iron deficient or that an unexplained low haemoglobin level should be treated without investigation.
How to read this profile
Scientific information relates to the ingredient and dosage-form context. It is not approved Luang Pharma labelling, a clinical recommendation, or evidence of equivalence to a referenced product. Multiple strengths or presentations represent separate proposed variants and must not be treated as interchangeable.
02 · Professional background
Scientific & clinical reference
Read the clinical context, selected safety considerations and presentation-specific information below.
Clinical context and therapeutic role
Assessment can include diet, pregnancy, blood loss, laboratory findings and disorders affecting absorption. Public-health programmes may use iron-folic acid combinations within specific protocols, while an individual patient may need investigation for bleeding, vitamin B12 deficiency or another cause of anaemia. The elemental iron amount is different from the mass of the iron salt. The hydrate form of the salt, folate content and approved intended use must therefore be checked in the product dossier.
Important safety considerations
Iron commonly causes gastrointestinal upset, constipation and dark stools. Accidental iron ingestion can be very dangerous for children, so secure storage is essential. Avoid unnecessary iron in iron-overload disorders, and review interactions with levothyroxine, certain antibiotics and other medicines. Folate can improve blood findings while vitamin B12-related neurological injury persists; unexplained anaemia needs appropriate diagnosis. Allergies and tolerability depend partly on the specific formulation.
These are selected considerations, not a complete list. Use the current instructions or approved label for the exact authorised product and seek appropriate professional advice.
Presentation, handling and storage
The iron salt is ferrous sulfate, the most widely used oral iron salt, and the strength is stated as elemental iron. The hydrate form, tablet type, excipients and elemental-iron assay must be established before a presentation is finalized. Programme-size bottles require suitable dispensing and traceability arrangements.
Keep the medicine in the labelled original pack with its leaflet. Check the expiry date and pack integrity before dispensing. The authorized label must determine storage temperature, protection from moisture or light, and disposal; no shelf life or in-use period can be established from a catalogue entry.
Final composition, instructions, shelf life and storage conditions are not established by this portfolio entry. They must come from the controlled documentation for the specific product.
Points for professional review
Confirm the clinical or programme rationale, relevant tests, iron-overload risk, vitamin B12 status when appropriate and medicine interactions. Verify elemental iron rather than assuming salt mass is equivalent.
03 · Product enquiry
Documentation & regulatory status
Evidence status
What is established — and what remains open
This record has received an editorial evidence-layer review. The review separates catalogue facts from unresolved product-specific fields and external context; it is not medical, regulatory or market-authorisation approval.
Layer 01
Controlled catalogue facts
- Generic ingredient
- Ferrous sulfate + folic acid
- Dosage form / presentation
- Tablet
- Catalogue strength
- Ferrous sulfate equivalent to 60 mg elemental iron + 400 mcg folic acid
- Catalogue pack
- Blister 10 x 10 tablets; bottle 1000 for programs
- Portfolio category
- Women's Health
Layer 02
Unresolved product-specific fields
- The iron salt is ferrous sulfate; its hydrate form (dried or heptahydrate), which sets the salt mass that provides 60 mg elemental iron, requires controlled documentation.
- Exact release/coating/scoring characteristics and formulation-specific administration instructions require controlled product documentation where applicable.
- Approved indication, patient eligibility and dosing are not established by this portfolio record.
- Registration, manufacturing/site status, supply availability, storage conditions and shelf life remain product- and market-specific evidence items.
Layer 03
Attributed external context
- NHS: ferrous sulfatepublic health service medicine information
- NHS: folic acidpublic health service medicine information
These references provide scientific or regulatory context only. They are not Luang Pharma product labelling, registration, manufacturing evidence, equivalence evidence or confirmation of supply.
Layer 04
Documents required to close the record
- Hydrate form and formula of the ferrous sulfate supporting the stated 60 mg elemental-iron quantity.
- Controlled product master/specification confirming the exact ingredient identity, dosage form, strength variant and pack mapping.
- Destination-market authorisation or other lawful supply-route evidence plus the approved label/leaflet/IFU, where applicable.
- Product-specific composition/excipient, storage, shelf-life and pack-control documentation.
- Manufacturing-site and supply-status evidence before any public claim of installed capability, registration, availability or equivalence.
For LP-102, identify the destination country, intended professional use, proposed presentation and the role of your organisation. The appropriate supply route and available documentation must be confirmed for that case.
- Confirm the legal entity, manufacturing site and authorised scope for the proposed supply chain.
- Confirm product registration or another lawful route, approved labelling and the applicable destination requirements.
- Request relevant product information, specifications and supporting evidence through the company contact.
- Confirm storage, transport, traceability, complaints and safety-reporting responsibilities before any agreement.
The public catalogue extends beyond the initial planned facility modules. A listing does not mean that the dosage form is installed, qualified or licensed at Boten.
04 · External sources
Sources and further reading
External sources are provided for reference. Their authors do not endorse Luang Pharma, and another product’s authorisation does not transfer to this portfolio record. Source availability and wording can change.
Professional enquiries
Request product-specific evidence for LP-102.
State the exact presentation, organisation, destination and evidence needed. This public record is not an offer of supply.